https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-8/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-and-actavis-to-present-linaclotide-data-at-the-american-college-of-gastroenterology-2014-annual-scientific-meeting-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2014-investor-update-call-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-initiation-of-phase-ii-trial-of-linaclotide-in-adult-patients-with-opioid-induced-constipation-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-presents-iw-9179-phase-iia-data-at-american-college-of-gastroenterology-2014-annual-scientific-meeting-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2014-investor-update-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-iii-trial-of-72-mcg-linaclotide-in-adult-patients-with-chronic-idiopathic-constipation-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-2014-healthcare-conference-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-earns-15-million-milestone-from-astellas-upon-initiation-of-enrollment-in-linaclotide-phase-iii-ibs-c-clinical-trial-in-japan-2/ 2023-01-09T07:51:18-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-iia-clinical-study-of-iw-9179-in-diabetic-gastroparesis-2/ 2023-01-09T07:51:17-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-15/ 2023-01-09T07:51:17-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-2014-investor-update-call-2/ 2023-01-09T07:51:17-05:00 https://ironwoodpharma.com/ironwood-reports-positive-top-line-data-from-exploratory-phase-iia-trial-of-iw-3718-in-refractory-gastroesophageal-reflux-disease-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-2014-investor-update-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-35th-annual-health-care-conference-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-barclays-global-healthcare-conference-8/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-i-clinical-study-of-sgc-stimulator-iw-1973-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/exact-sciences-and-ironwood-pharmaceuticals-enter-co-promotion-agreement-for-cologuard-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2015-investor-update-call-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-lawrence-olanoff-m-d-ph-d-to-board-of-directors-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2015-investor-update-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2015-health-care-conference-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-presents-gastrointestinal-disease-research-at-digestive-disease-week-2015-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-goldman-sachs-36th-annual-global-healthcare-conference-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-proposed-offering-of-300-million-of-convertible-senior-notes-2/ 2023-01-09T07:51:16-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-prices-300-million-of-convertible-senior-notes-2/ 2023-01-09T07:51:15-05:00 https://ironwoodpharma.com/astrazeneca-and-ironwood-report-positive-top-line-data-from-phase-iii-ibs-c-trial-designed-to-support-linaclotide-approval-in-china-2/ 2023-01-09T07:51:15-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2015-investor-update-call-2/ 2023-01-09T07:51:15-05:00 https://ironwoodpharma.com/ironwood-progresses-sgc-stimulator-platform-with-positive-top-line-phase-i-data-on-iw-1973-2/ 2023-01-09T07:51:15-05:00 https://ironwoodpharma.com/ironwood-and-allergan-enter-agreement-to-co-promote-viberzi-for-irritable-bowel-syndrome-with-diarrhea-ibs-d-in-the-u-s-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2015-investor-update-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-7/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-reports-positive-top-line-results-from-phase-iii-trial-of-72-mcg-linaclotide-in-adults-with-chronic-idiopathic-constipation-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2015-investor-update-call-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-highlights-refractory-gerd-and-constipation-research-at-the-american-college-of-gastroenterology-2015-annual-scientific-meeting-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/allergan-acquires-rights-to-ironwoods-constella-linaclotide-from-almirall-in-more-than-40-countries-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-and-allergan-initiate-phase-iib-clinical-trial-of-linaclotide-colonic-release-in-adults-with-irritable-bowel-syndrome-with-constipation-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-clinical-studies-of-soluble-guanylate-cyclase-stimulators-iw-1973-and-iw-1701-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2015-investor-update-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-24th-annual-healthcare-conference-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/ironwood-reports-positive-top-line-data-from-phase-ii-trial-of-linaclotide-in-adult-patients-with-opioid-induced-constipation-2/ 2023-01-09T07:51:14-05:00 https://ironwoodpharma.com/astellas-and-ironwood-report-positive-top-line-data-from-phase-iii-ibs-c-trial-conducted-in-japan-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-14/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-details-strategy-to-build-top-performing-commercial-biotechnology-company-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2015-investor-update-call-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-2016-rbc-capital-markets-global-healthcare-conference-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2015-investor-update-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-progresses-vascular-and-fibrotic-disease-platform-with-positive-top-line-phase-ia-data-on-soluble-guanylate-cyclase-stimulator-iw-1701-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-filing-by-astellas-of-new-drug-application-in-japan-with-linaclotide-for-the-treatment-of-adults-with-ibs-c-2/ 2023-01-09T07:51:13-05:00 https://ironwoodpharma.com/video-alert-updated-2016-direct-to-consumer-awareness-campaign-available-for-linzess-linaclotide-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-36th-annual-health-care-conference-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-barclays-global-healthcare-conference-7/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-iib-clinical-trial-of-iw-3718-in-refractory-gastroesophageal-reflux-disease-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-clinical-and-preclinical-data-on-sgc-stimulators-at-upcoming-scientific-conferences-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-top-line-data-from-exploratory-phase-iia-study-of-iw-9179-in-diabetic-gastroparesis-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-andrew-dreyfus-to-board-of-directors-2/ 2023-01-09T07:51:12-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2016-investor-update-call-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-enters-into-u-s-licensing-agreement-with-astrazeneca-for-lesinurad-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2016-health-care-conference-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2016-investor-update-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-linaclotide-data-at-digestive-disease-week-2016-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-2016-ubs-global-healthcare-conference-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-goldman-sachs-37th-annual-global-healthcare-conference-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-closes-u-s-transaction-with-astrazeneca-for-lesinurad-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-jefferies-2016-healthcare-conference-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-supplemental-new-drug-application-for-72-mcg-linaclotide-in-chronic-idiopathic-constipation-has-been-accepted-for-fda-review-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2016-investor-update-call-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2016-investor-update-2/ 2023-01-09T07:51:11-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-wells-fargo-2016-healthcare-conference-2/ 2023-01-09T07:51:10-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-6/ 2023-01-09T07:51:10-05:00 https://ironwoodpharma.com/ironwood-closes-150-million-debt-refinancing-2/ 2023-01-09T07:51:10-05:00 https://ironwoodpharma.com/nine-in-ten-physicians-agree-target-goal-for-gout-is-imperative-yet-half-of-patients-fail-to-reach-it-new-survey-shows-2/ 2023-01-09T07:51:10-05:00 https://ironwoodpharma.com/ironwood-announces-u-s-availability-of-zurampic-lesinurad-200-mg-tablets-for-patients-with-uncontrolled-gout-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2016-investor-update-call-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-highlights-breadth-of-gout-research-with-presentations-at-the-american-college-of-rheumatology-2016-annual-meeting-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-25th-annual-healthcare-conference-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2016-investor-update-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-stifel-2016-healthcare-conference-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-highlights-zurampic-lesinurad-phase-iii-extension-study-data-at-the-american-college-of-rheumatology-2016-annual-meeting-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-approval-of-linzess-linaclotide-in-japan-for-the-treatment-of-adults-with-ibs-c-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-and-allergan-report-topline-phase-iib-data-supporting-further-investigation-of-linaclotide-colonic-release-2-cr2-for-abdominal-pain-in-non-constipation-subtypes-of-ibs-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-and-allergan-report-topline-phase-iib-data-supporting-advancement-of-linaclotide-colonic-release-1-cr1-in-ibs-c-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-13/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-announces-new-drug-application-for-duzallo-fixed-dose-combination-of-lesinurad-and-allopurinol-has-been-accepted-for-fda-review-2/ 2023-01-09T07:51:09-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-amy-schulman-to-board-of-directors-2/ 2023-01-09T07:51:08-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-demonstrates-strong-execution-on-strategy-to-build-top-performing-commercial-biotech-2/ 2023-01-09T07:51:08-05:00 https://ironwoodpharma.com/u-s-food-and-drug-administration-approves-72-mcg-dose-of-linzess-linaclotide-for-adults-with-chronic-idiopathic-constipation-2/ 2023-01-09T07:51:08-05:00 https://ironwoodpharma.com/astellas-and-ironwood-report-positive-top-line-results-from-phase-iii-linaclotide-trial-for-patients-with-chronic-constipation-conducted-in-japan-2/ 2023-01-09T07:51:08-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2016-investor-update-call-2/ 2023-01-09T07:51:08-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2016-investor-update-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-rd-day-on-march-9-2017-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-37th-annual-health-care-conference-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-showcases-progress-delivering-innovative-medicines-to-patients-and-building-a-top-performing-commercial-biotech-at-rd-day-2017-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-barclays-global-healthcare-conference-6/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-dr-christopher-wright-as-senior-vice-president-of-global-development-and-chief-development-officer-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/allergan-and-ironwood-launch-campaign-designed-to-empower-the-nearly-64-million-americans-estimated-to-suffer-from-ibs-and-cic-to-talk-about-bowel-health1-5-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2017-investor-update-call-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-new-data-for-linaclotide-linaclotide-delayed-release-and-iw-1701-at-digestive-disease-week-2017-2/ 2023-01-09T07:51:07-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2017-investor-update-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-presents-data-further-elucidating-linaclotides-effect-on-pain-at-digestive-disease-week-2017-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2017-investor-update-call-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-positive-top-line-results-from-iw-3718-phase-iib-trial-in-uncontrolled-gastroesophageal-reflux-disease-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2017-investor-update-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-fda-approval-of-duzallo-lesinurad-and-allopurinol-for-the-treatment-of-hyperuricemia-in-patients-with-uncontrolled-gout-2/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-6/ 2023-01-09T07:51:06-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-leadership-change-2/ 2023-01-09T07:51:05-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-presenting-linaclotide-data-at-the-world-congress-of-gastroenterology-at-acg-2017-2/ 2023-01-09T07:51:05-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2017-investor-update-call-2/ 2023-01-09T07:51:05-05:00 https://ironwoodpharma.com/ironwood-highlights-breadth-of-gout-research-to-be-presented-at-the-2017-acr-arhp-annual-meeting-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-26th-annual-healthcare-conference-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2017-investor-update-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-strengthens-executive-leadership-team-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-reports-top-line-phase-iia-data-for-iw-1973-demonstrating-positive-cardiovascular-metabolic-and-endothelial-effects-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-ii-clinical-trial-of-sgc-stimulator-iw-1701-in-patients-with-sickle-cell-disease-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-12/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-settlement-with-sun-pharma-resolving-linzess-linaclotide-patent-litigation-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2017-investor-update-call-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2017-investor-update-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-march-investor-conferences-4/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-director-nomination-from-sarissa-capital-2/ 2023-01-09T07:51:04-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2018-investor-update-call-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/allergan-and-ironwood-launch-interactive-digital-destination-during-irritable-bowel-syndrome-ibs-awareness-month-designed-to-encourage-sufferers-to-get-educated-and-take-action-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2018-investor-update-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-intent-to-separate-soluble-guanylate-cyclase-sgc-business-from-commercial-and-gastrointestinal-business-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-files-definitive-proxy-materials-and-mails-letter-to-shareholders-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-settlement-with-aurobindo-pharma-resolving-linzess-linaclotide-patent-litigation-2/ 2023-01-09T07:51:03-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-files-investor-presentation-highlighting-actions-taken-designed-to-unlock-shareholder-value-2/ 2023-01-09T07:51:01-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-sends-letter-to-shareholders-highlighting-director-nominees-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-highlight-clinical-data-for-iw-3718-in-persistent-gastroesophageal-reflux-disease-gerd-at-digestive-disease-week-2018-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-results-of-2018-annual-meeting-of-shareholders-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-presents-iw-3718-data-showing-improvements-in-heartburn-and-regurgitation-symptoms-in-patients-with-persistent-gerd-at-digestive-disease-week-2018-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-fda-orphan-drug-designation-for-olinciguat-for-the-treatment-of-sickle-cell-disease-2/ 2023-01-09T07:51:00-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-highlight-clinical-and-preclinical-data-for-praliciguat-at-the-american-diabetes-associations-78th-scientific-sessions-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-pivotal-phase-iii-program-for-iw-3718-in-persistent-gastroesophageal-reflux-disease-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-presents-praliciguat-phase-iia-study-data-showing-positive-impact-on-metabolic-and-cardiovascular-clinical-endpoints-at-the-american-diabetes-associations-78th-scientific-sessions-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-iiib-study-of-linaclotide-in-adult-patients-with-irritable-bowel-syndrome-with-constipation-ibs-c-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2018-investor-update-call-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2018-investor-update-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/approval-of-linzess-tablets-0-25-mg-in-japan-for-additional-indication-of-chronic-constipation-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-5/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-fda-fast-track-designation-for-praliciguat-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction-hfpef-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-presenting-iw-3718-and-linaclotide-data-at-the-american-college-of-gastroenterology-2018-annual-scientific-meeting-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2018-investor-update-call-2/ 2023-01-09T07:50:59-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2018-investor-update-2/ 2023-01-09T07:50:58-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-27th-annual-credit-suisse-healthcare-conference-2/ 2023-01-09T07:50:58-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-settlement-with-mylan-resolving-linzess-linaclotide-patent-litigation-2/ 2023-01-09T07:50:57-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-11/ 2023-01-09T07:50:57-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-chief-executive-officers-to-lead-ironwood-and-cyclerion-effective-upon-upcoming-separation-2/ 2023-01-09T07:50:57-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-michael-shetzline-m-d-ph-d-as-chief-medical-officer-2/ 2023-01-09T07:50:57-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-approval-of-linzess-linaclotide-in-china-for-the-treatment-of-adults-with-ibs-c-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-announces-filing-of-form-10-registration-statement-in-connection-with-planned-business-separation-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2018-investor-update-call-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2018-investor-update-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-svb-leerink-global-healthcare-conference-4/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/cyclerion-the-planned-rd-spin-off-of-ironwood-pharmaceuticals-secures-commitments-of-175-million-in-private-offering-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-health-care-conference-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-barclays-global-healthcare-conference-5/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-announces-effectiveness-of-cyclerion-form-10-registration-statement-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-completes-separation-of-cyclerion-therapeutics-and-becomes-a-gastrointestinal-gi-focused-healthcare-company-2/ 2023-01-09T07:50:56-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-adjustment-of-conversion-rate-for-its-2-25-convertible-senior-notes-due-2020-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2019-investor-update-call-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2019-results-announces-positive-2019-adjusted-ebitda-from-continuing-operations-guidance-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-2019-bank-of-america-merrill-lynch-healthcare-conference-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-highlight-iw-3718-and-linaclotide-data-at-digestive-disease-week-2019-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-allergan-initiate-patient-dosing-in-phase-ii-clinical-trial-of-md-7246-in-patients-with-abdominal-pain-associated-with-ibs-d-2/ 2023-01-09T07:50:55-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-establish-new-headquarters-in-downtown-boston-2/ 2023-01-09T07:50:54-05:00 https://ironwoodpharma.com/ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c-2/ 2023-01-09T07:50:54-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2019-investor-update-call-2/ 2023-01-09T07:50:54-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-second-quarter-2019-results-2/ 2023-01-09T07:50:54-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announced-proposed-offering-of-330-million-of-convertible-senior-notes-2/ 2023-01-09T07:50:54-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-pricing-of-upsized-350-million-convertible-senior-notes-offering-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-alnylam-pharmaceuticals-enter-u-s-gi-disease-education-and-promotional-agreement-for-alnylams-givosiran-in-acute-hepatic-porphyria-ahp-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-full-exercise-of-convertible-notes-over-allotment-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-4/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-astrazeneca-amend-linzess-linaclotide-collaboration-in-china-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2019-investor-update-call-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-highlight-new-data-at-the-american-college-of-gastroenterology-2019-annual-scientific-meeting-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-third-quarter-2019-results-raises-full-year-2019-guidance-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-28th-annual-credit-suisse-healthcare-conference-2/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-10/ 2023-01-09T07:50:53-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-settlement-resolving-linzess-linaclotide-patent-litigation-2/ 2023-01-09T07:50:52-05:00 https://ironwoodpharma.com/ironwood-and-allergan-announce-settlement-with-teva-resolving-linzess-linaclotide-patent-litigation-2/ 2023-01-09T07:50:52-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2019-investor-update-call-2/ 2023-01-09T07:50:52-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-fourth-quarter-and-full-year-2019-results-exceeding-full-year-2019-guidance-provides-full-year-2020-guidance-2/ 2023-01-09T07:50:52-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-svb-leerink-global-healthcare-conference-3/ 2023-01-09T07:50:52-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-march-investor-conferences-3/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-publication-of-positive-iw-3718-phase-iib-data-in-gastroenterology-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/a-message-to-our-healthcare-providers-patients-and-other-partners-during-covid-19-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-update-on-impact-of-covid-19-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2020-investor-update-call-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-and-allergan-receive-notices-of-allowance-for-patent-applications-covering-72-mcg-dose-of-linzess-linaclotide-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2020-results-and-provides-update-on-impact-of-covid-19-pandemic-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-and-abbvie-report-top-line-phase-ii-data-for-md-7246-in-patients-with-abdominal-pain-associated-with-irritable-bowel-syndrome-with-diarrhea-ibs-d-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-announces-updates-designed-to-strengthen-iw-3718-phase-iii-program-for-refractory-gastroesophageal-reflux-disease-gerd-2/ 2023-01-09T07:50:51-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2020-investor-update-call-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-second-quarter-2020-results-delivered-gaap-net-income-of-25-million-and-adjusted-ebitda-of-33-million-2/ 2023-01-09T07:50:50-05:00